SC: Suit Alleging Coercion or Undue Influence Cannot be Rejected under Order VII Rule 11 CPC  ||  Cal HC: Once ED Attachment is Confirmed, Challenge Becomes Academic; PMLA Remedy Must be Pursued  ||  MP HC: Pen-Drive Evidence Cannot be Introduced At a Late Trial Stage Without Proof or Relevance  ||  Calcutta HC: Employee Can't be Stopped From Joining Rival Post-Resignation; Trade Secrets Protected  ||  Calcutta HC: Banks Must Provide Forensic Audit Report Before Calling an Account Fraudulent  ||  Del HC: Woman Cannot Demand Re-Entry to Abandoned Matrimonial Home if Alternate Accommodation Exists  ||  Calcutta HC: Land Acquisition For Industrial Park is Public Purpose; Leasing to Industry is Valid  ||  Patna HC: PwD Recruitment Must Comply With RPwD Act; Executive Resolutions Cannot Override the Law  ||  Madras HC: Individuals Facing Criminal Trial Must Get Court Permission Even to Renew Passports  ||  Calcutta HC: Demolition Orders Cannot be Challenged under Article 226 if a Statutory Appeal Exists    

Roche Products v. Drugs Controller General of India and ors - (High Court of Delhi) (25 Apr 2016)

Delhi High Court to delve into Drug Controller irregularities

Civil

The Delhi High Court deferred a dispute regarding the development, classification and promotion of bio-similar drugs to 2 June 2016. Brought by Roche Products, the plaint raised concerns about irregularities by the Drug Controller General of India in granting approval to Biocon Limited and Mylan Pharmaceuticals for a bio-similar drug in five days - a process which usually takes much longer than that due to deliberation by three separate bodies, before it reaches the DCGI. The drug in question is Trastuzumab, used for treatment of breast cancer.

The Court accepted Roche’s arguments, ruling that “approvals…are not on the basis of the adherence of the Guidelines of 2012 and rules framed”. However, final finding would be arrived at upon completion of trial. The Defendants were allowed to continue manufacturing and marketing their drug claiming bio-similarity with Roche’s drug, but with certain provisos on indication used on packaging.

Tags : TRASTUZUMAB   BIO-SIMILAR   DCGI   ROCHE  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved